Prosecution Insights
Last updated: April 19, 2026
Application No. 18/548,747

4-AMINO-6-OXO-PYRIDAZINE DERIVATIVES MODULATING NLRP3

Non-Final OA §112
Filed
Sep 01, 2023
Examiner
CHICKS, ASHLI ARIANA
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Janssen Pharmaceutica NV
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
3y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allow Rate
49 granted / 75 resolved
+5.3% vs TC avg
Strong +44% interview lift
Without
With
+43.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
37 currently pending
Career history
112
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
29.9%
-10.1% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
23.6%
-16.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 75 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 1-10, 12 and 14-17 are pending. Claims 1-10, 12 and 14-17 are rejected. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-10, 12 and 14-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 1, 2, and 17, the phrase "for example" or “e.g.” renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claims 3-6, 8-10, 12 and 14-16 are rejected as failing to obviate the indefiniteness of claim 1. Regarding claims 4, the phrase "for instance" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 7, the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Additionally, the claims should be free of parenthetical expressions as it is unclear if these limitations are optional or required by the claims. For example, the following is from page 4, lines 2 and 12-16 of claim 1: PNG media_image1.png 70 688 media_image1.png Greyscale PNG media_image2.png 246 784 media_image2.png Greyscale . See page 5, lines 19 and 26-33 of claim 2; line 6 of claim 3; line 12 of claim 7; and page 10 lines 5 and 12-19 of claim 17. Claim 17 recites the limitation "the compound of formula (IV)" in line 2. There is insufficient antecedent basis for this limitation in the claim. Claim 17 is further rejected as indefinite as it is unclear how the compound of formula (IV) is involved in the active steps of the method of preparing. Closest Prior Art The closest prior art appears to be by Gladysz et al. ((2014), Repositioning the Substrate Activity Screening (SAS) Approach as a Fragment-Based Method for Identification of Weak Binders. ChemBioChem, 15: 2238-2247.) The prior art discloses compound 25 which is analogous to a compound of formula (I) where R1 is a 10-memebered bicyclic heteroaryl substituted by C1 alkyl, R3a and R3b are linked together to form a 6-membered cyclic group containing an additional nitrogen heteroatom, and R4 is halo (page 2241, Table 1): PNG media_image3.png 206 570 media_image3.png Greyscale PNG media_image4.png 100 541 media_image4.png Greyscale . The prior art compound differs from the instant compounds as it lacks a substituent corresponding to variable R2 and the heteroaryl of R1 is substituted with oxo. Gladysz et al. explored the effect of modifying prior art fragment R on the inhibition of urokinase (uPA) however none of the other prior art compounds prepared contain the oxo-pyrdazine core required of the instant compounds. Furthermore, Gladyysz et al. provide no motivation or guidance for modifying the prior art compound further to introduce substituents or provide additional permutations of the compound that would be fully embraced by instant formula (I). For these reasons, the prior art neither anticipates nor renders obvious the instant claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ASHLI A CHICKS whose telephone number is (571)270-0582. The examiner can normally be reached M-Th 7 a.m.- 5 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at (571)272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.A.C./Examiner, Art Unit 1626 /MATTHEW P COUGHLIN/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Sep 01, 2023
Application Filed
Jan 31, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589107
COMPOSITION CONTAINING NICOTINAMIDE MONONUCLEOTIDE AND MOGROSIDE, AND APPLICATION THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12590088
JAK INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
2y 5m to grant Granted Mar 31, 2026
Patent 12564552
ORAL PRODUCT WITH A BASIC AMINE AND AN ION PAIRING AGENT
2y 5m to grant Granted Mar 03, 2026
Patent 12552801
NEW INDAZOLE DERIVATIVES
2y 5m to grant Granted Feb 17, 2026
Patent 12540130
SUBSTITUTED PYRROLIDINE AMIDES IV
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+43.9%)
3y 3m
Median Time to Grant
Low
PTA Risk
Based on 75 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month